Company Presentation January 2013 - Epigenomics AG

More documents

Recommendations

Info

CRC Tumorgenesis and Septin9 32 | January 2013
Septin9 Tests: Continious Improvement as Assay Technology Evolved Sensitivity / Specificity 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 33 | January 2013 1 2 3 4 5 6 7 8 9 10 11 12 13 Technology Development 1 st Gen. Tests Epi proColon® Case Control Studies 5.000 4.500 4.000 3.500 3.000 2.500 2.000 1.500 1.000 500 0 Subjects tested (cumulative)
Page 1 and 2: Epigenomics AG Corporate Presentati
Page 3 and 4: Contents � Epigenomics overview
Page 5 and 6: Key Financials 9M 2012 � Tightly
Page 7 and 8: Colorectal Cancer (CRC) Screening S
Page 9 and 10: Blood-based Screening is Widely Acc
Page 11 and 12: Methylated Septin9 is a Suitable Ma
Page 13 and 14: Epi proColon®: One Assay - One Mar
Page 15 and 16: Fecal Immunochemical Test (FIT) Com
Page 17 and 18: Comparison Study Top Line Data: Sen
Page 19 and 20: Comparison Study Top Line Data: Det
Page 21 and 22: FDA Submission Status: Completed in
Page 23 and 24: Expected US Product Launch of Epi p
Page 25 and 26: Epi proLung® - Market Introduction
Page 27 and 28: Contents � Epigenomics overview
Page 29 and 30: Why Invest in Epigenomics.... 29 |
Page 31: Contents � Epigenomics overview

Company Presentation January 2013 - Epigenomics AG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?